Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus standard amoxicillin course for erysipelas
2016-002249-53Phase 4
Key facts
- Status
- Active
- Start
- Jan 2023
- Countries
- 1
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Drugs
- amoxicillin
- Conditions
- erysipelascellulitispyoderma gangrenosum (PG)
01
Overview
Phase 4, randomised, single-blind trial of amoxicillin in erysipelas, cellulitis and pyoderma gangrenosum (PG) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete remission at end of oral treatment. Started Jan 2023; status: active.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Short-course amoxicillin
Amoxicillin 50 mg/kg for 5 days.
Standard-course amoxicillin
Amoxicillin 50 mg/kg for 10 days.
03
Who it enrols
Adults aged 18 years or older with lower-limb erysipelas or cellulitis; excludes patients with beta-lactam allergy or fructose intolerance.
04
Endpoints
Primary
Complete remission at end of oral treatment
Secondary
Clinical remission rate
Beyond the preview
Go deeper on 2016-002249-53.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002249-53.